On April 23, 2026, Nano‑X Imaging Ltd. announced that its U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems, a nationwide provider of diagnostic imaging and oncology equipment. The partnership will enable Radiology Oncology Systems to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across the United States, leveraging its established distribution network and service infrastructure to accelerate deployment in hospitals and clinics.
The Nanox.ARC system is FDA‑cleared under 510(k) for general use, including musculoskeletal, pulmonary, intra‑abdominal, and paranasal indications, and received clearance for the TAP2D image‑enhancement capability in February 2026. The system delivers 3‑D imaging at a lower radiation dose and cost than traditional CT scanners, positioning it as a practical, accessible solution for oncology‑adjacent care environments.
Nano‑X’s recent financial results illustrate the challenges it faces as it scales its technology. In Q4 2025 the company reported revenue of $3.7 million and a net loss of $33.4 million, while Q1 2025 revenue was $2.8 million with a net loss of $13.2 million. Teleradiology services generated $3.1 million in Q4 2025, achieving a gross profit margin of 48%, whereas imaging system sales produced only $49,000 in revenue and a $2.6 million gross loss. The company’s cash balance stood at $60 million as of December 31, 2025, and it has set a 2026 revenue target of $35 million, with the second half expected to be driven by channel activation and system installations.
Management emphasized the strategic value of the partnership. CEO Erez Meltzer said, "We continue to systematically expand our U.S. commercial footprint through targeted distribution agreements. Radiology Oncology Systems adds another experienced partner to our growing U.S. network, bringing specialized expertise in oncology and diagnostic imaging that complements our existing channel partners and supports measured deployment and continued commercial execution." President John Vano added, "We are pleased to enter into this agreement with Nanox. We believe the Nanox.ARC aligns well with our focus on delivering practical, accessible imaging solutions to U.S. healthcare providers."
The agreement is a key step in Nano‑X’s effort to convert its pipeline into revenue, but the company remains in a loss position due to restructuring charges, a $17.5 million impairment related to its South Korean manufacturing operations, and ongoing investment in R&D and marketing. The partnership with Radiology Oncology Systems is expected to reduce customer acquisition costs and provide a robust service network, potentially improving gross margins on system sales. However, the competitive landscape—dominated by established imaging giants and AI‑focused startups—remains a significant headwind. Investors previously reacted negatively to Nano‑X’s Q4 2025 earnings, with shares falling 16.32 % after the report, underscoring the market’s sensitivity to the company’s profitability trajectory.
In summary, the distribution agreement expands Nano‑X’s U.S. reach and leverages a partner with deep oncology and imaging expertise, offering a pathway to scale the Nanox.ARC system. While the partnership may help accelerate revenue growth, the company’s ongoing losses, high operating expenses, and competitive pressures suggest that the deal’s impact will be incremental until Nano‑X can achieve sustainable profitability and scale its high‑margin teleradiology services alongside its hardware offerings.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.